Discontinued — last reported Q4 '17
An increase suggests higher capital intensity or significant recent acquisitions of intangible assets, while a decrease may indicate aging assets or reduced capital expenditure cycles.
This metric represents the non-cash expense allocated to the systematic reduction of the carrying value of tangible and...
Comparable to D&A line items in segment reporting for other large-cap pharmaceutical companies, often reflecting the amortization of acquired drug patents and manufacturing infrastructure.
mrk_segment_operating_segments_depreciation_depletion_and_amortization